Janssen Adcom Documents Look Promising for Gilead
By Mari Serebrov
Tuesday, October 22, 2013
No big worries appear to be on the agenda for Thursday’s advisory committee meeting on Janssen Pharmaceuticals Inc.’s simeprevir, which is seeking a limited hepatitis C virus (HCV) label.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.